- TAH3311 is an oral dissolving film formulation of apixaban.
- The pivotal trial enrolled 60 volunteers to evaluate the formulation.
- TAH3311 is intended for use by patients with swallowing difficulties, including elderly patients, stroke survivors, and pediatric patients.
- Apixaban had U.S. sales of $22.1 billion in 2023.
- TAHO Pharmaceuticals aims to transform how anticoagulant therapies are delivered.
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
